文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

超越药敏:现有口服抗生素在广泛耐药伤寒中的药代动力学与药效学限制

Beyond susceptibility: pharmacokinetic and pharmacodynamic constraints of existing oral antibiotics in extensively drug-resistant typhoid fever.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

本文综述了伤寒沙门菌感染口服治疗现状,指出广泛耐药菌株使口服选择大幅收窄。阿奇霉素是唯一广泛可用且具临床疗效的口服药物,但耐药威胁其地位。美西林、法罗培南等体外有效,但缺乏稳健临床疗效和当代PK/PD数据支持其用于MDR/XDR伤寒。

要点

  • 阿奇霉素是当前唯一广泛可用且具临床疗效的口服抗伤寒药物。
  • 美西林、法罗培南等体外有效但缺乏临床与PK/PD证据支持XDR伤寒。
  • 需整合PK/PD研究与前瞻性临床试验以扩展口服治疗选择。

核心结论

  • 现有口服抗生素在广泛耐药伤寒中受PK/PD限制,阿奇霉素是唯一广泛可用且具临床疗效的口服药物,但耐药威胁其持续使用。

研究设计与样本

  • 本文为综述,围绕伤寒沙门菌的PK/PD特征与现有口服抗生素的临床证据进行论述。

主要发现

  • MDR与XDR伤寒沙门菌的出现显著收窄了可用口服治疗选择。
  • 美西林、法罗培南、替比培南、磷霉素及β-内酰胺/β-内酰胺酶抑制剂组合对伤寒沙门菌显示良好体外活性,但缺乏稳健临床疗效与当代PK/PD数据支持其用于MDR和XDR伤寒。

关键数值与推荐

  • 阿奇霉素仍是唯一广泛可用且具确立临床疗效的口服药物,但新发耐药威胁其持续效用。

临床怎么用

  • 临床决策应以临床疗效为核心,PK/PD分析可辅助剂量优化并揭示候选药物的药理局限。
  • 在MDR/XDR伤寒中,不应仅凭体外活性选用替代口服药物,需等待稳健临床与PK/PD证据。

局限性

  • 替代口服药物缺乏稳健临床疗效与当代PK/PD数据,证据缺口需通过整合PK/PD研究与前瞻性临床试验解决。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Salmonella Typhi is an invasive pathogen with sustained bacteraemia and intracellular persistence, requiring therapy that achieves systemic exposure and intracellular penetration. Clinical efficacy should remain central to therapeutic decision-making, while pharmacokinetic/pharmacodynamic (PK/PD) analyses provide complementary insights into dose optimization and the pharmacological limitations of candidate therapies. Oral therapy remains central to typhoid fever management, particularly in South and Southeast Asia, where most patients are managed in the outpatient setting. However, the emergence of MDR and extensively drug-resistant (XDR) S. Typhi has substantially narrowed the available oral treatment options. Azithromycin remains the only widely available oral agent with established clinical efficacy, but emerging resistance threatens its continued utility. Several alternative oral agents, including mecillinam, faropenem, tebipenem, fosfomycin and β-lactam/β-lactamase inhibitor combinations, demonstrate favourable in vitro activity against S. Typhi. However, robust clinical efficacy and contemporary PK/PD data are lacking to support their use against MDR and XDR S. Typhi. Addressing these evidence gaps through integrated PK/PD investigations and prospective clinical trials will be essential to expand the oral therapeutic armamentarium for typhoid fever.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Bakthavatchalam YD, Rupali P, John J, et al. Beyond susceptibility: pharmacokinetic and pharmacodynamic constraints of existing oral antibiotics in extensively drug-resistant typhoid fever. J Antimicrob Chemother. 2026. PMID: 42841931. doi:10.1093/jac/dkag332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。